{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T20:42:41Z","timestamp":1789764161155,"version":"4.0.1"},"reference-count":38,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2017,6,16]],"date-time":"2017-06-16T00:00:00Z","timestamp":1497571200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81472816"],"award-info":[{"award-number":["81472816"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["31300756"],"award-info":[{"award-number":["31300756"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007847","name":"Natural Science Foundation of Jilin Province","doi-asserted-by":"publisher","award":["20160101240JC"],"award-info":[{"award-number":["20160101240JC"]}],"id":[{"id":"10.13039\/100007847","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004032","name":"Jilin University","doi-asserted-by":"publisher","award":["2016151"],"award-info":[{"award-number":["2016151"]}],"id":[{"id":"10.13039\/501100004032","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0179476","type":"journal-article","created":{"date-parts":[[2017,6,16]],"date-time":"2017-06-16T17:31:02Z","timestamp":1497634262000},"page":"e0179476","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":15,"title":["Therapeutic efficacy of AAV8-mediated intrastriatal delivery of human cerebral dopamine neurotrophic factor in 6-OHDA-induced parkinsonian rat models with different disease progression"],"prefix":"10.1371","volume":"12","author":[{"given":"Lizheng","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zixuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinpeng","family":"Bi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyao","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenmo","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haihong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7739-1386","authenticated-orcid":true,"given":"Xianghui","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2017,6,16]]},"reference":[{"issue":"4","key":"ref1","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1159\/000445751","article-title":"The Incidence of Parkinson's Disease: A Systematic Review and Meta-Analysis","volume":"46","author":"L Hirsch","year":"2016","journal-title":"Neuroepidemiology"},{"issue":"8","key":"ref2","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/35086062","article-title":"Pathophysiology of levodopa-induced dyskinesia: Potential for new therapies","volume":"2","author":"E Bezard","year":"2001","journal-title":"Nat Rev Neurosci"},{"issue":"3","key":"ref3","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1172\/JCI71640","article-title":"Serotonergic mechanisms responsible for levodopa-induced dyskinesias in Parkinson's disease patients","volume":"124","author":"M Politis","year":"2014","journal-title":"J Clin Invest"},{"issue":"2","key":"ref4","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s00415-010-5796-9","article-title":"Gene therapy: a viable therapeutic strategy for Parkinson's disease?","volume":"258","author":"AL Berry","year":"2011","journal-title":"J Neurol"},{"issue":"20","key":"ref5","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1212\/WNL.0b013e3181c29356","article-title":"Safety and tolerability of putaminal AADC gene therapy for Parkinson disease","volume":"73","author":"CW Christine","year":"2009","journal-title":"Neurology"},{"issue":"21","key":"ref6","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1212\/01.wnl.0000312381.29287.ff","article-title":"Results from a phase I safety trial of hAADC gene therapy for Parkinson disease","volume":"70","author":"JL Eberling","year":"2008","journal-title":"Neurology"},{"issue":"9923","key":"ref7","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/S0140-6736(13)61939-X","article-title":"Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1\/2 trial","volume":"383","author":"S Palfi","year":"2014","journal-title":"Lancet"},{"issue":"8","key":"ref8","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1089\/hum.2015.065","article-title":"Prospects of Neurotrophic Factors for Parkinson's Disease: Comparison of Protein and Gene Therapy","volume":"26","author":"A Domanskyi","year":"2015","journal-title":"Human gene therapy"},{"issue":"1","key":"ref9","first-page":"31","article-title":"Single administration of GDNF into the striatum induced protection and repair of the nigrostriatal dopaminergic system in the intrastriatal 6-hydroxydopamine injection model of hemiparkinsonism","volume":"17","author":"M Aoi","year":"2000","journal-title":"Restor Neurol Neuros"},{"issue":"1","key":"ref10","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.nbd.2005.06.015","article-title":"Functional reinnervation from remaining DA terminals induced by GDNF lentivirus in a rat model of early Parkinson's disease","volume":"21","author":"M Brizard","year":"2006","journal-title":"Neurobiology of disease"},{"issue":"2","key":"ref11","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0006-8993(02)02934-7","article-title":"Dopaminergic neuroprotection and regeneration by neurturin assessed by using behavioral, biochemical and histochemical measurements in a model of progressive Parkinson's disease","volume":"947","author":"Y Oiwa","year":"2002","journal-title":"Brain Res"},{"issue":"5","key":"ref12","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1046\/j.1460-9568.1999.00566.x","article-title":"Protection and regeneration of nigral dopaminergic neurons by neurturin or GDNF in a partial lesion model of Parkinson's disease after administration into the striatum or the lateral ventricle","volume":"11","author":"C Rosenblad","year":"1999","journal-title":"Eur J Neurosci"},{"issue":"5","key":"ref13","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/nm850","article-title":"Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease","volume":"9","author":"SS Gill","year":"2003","journal-title":"Nature medicine"},{"issue":"1","key":"ref14","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1212\/WNL.60.1.69","article-title":"Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD","volume":"60","author":"JG Nutt","year":"2003","journal-title":"Neurology"},{"issue":"3","key":"ref15","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1002\/ana.20737","article-title":"Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease","volume":"59","author":"AE Lang","year":"2006","journal-title":"Annals of neurology"},{"issue":"9579","key":"ref16","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1016\/S0140-6736(07)60982-9","article-title":"Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial","volume":"369","author":"MG Kaplitt","year":"2007","journal-title":"Lancet"},{"issue":"12","key":"ref17","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/S1474-4422(10)70254-4","article-title":"Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial","volume":"9","author":"WJ Marks Jr.","year":"2010","journal-title":"Lancet Neurol"},{"issue":"5","key":"ref18","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/S1474-4422(08)70065-6","article-title":"Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial","volume":"7","author":"WJ Marks","year":"2008","journal-title":"Lancet Neurol"},{"issue":"4","key":"ref19","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1093\/protein\/gzn080","article-title":"The structure of the conserved neurotrophic factors MANF and CDNF explains why they are bifunctional","volume":"22","author":"V Parkash","year":"2009","journal-title":"Protein Eng Des Sel"},{"issue":"30","key":"ref20","doi-asserted-by":"crossref","first-page":"9651","DOI":"10.1523\/JNEUROSCI.0833-09.2009","article-title":"Mesencephalic Astrocyte-Derived Neurotrophic Factor Is Neurorestorative in Rat Model of Parkinson's Disease","volume":"29","author":"MH Voutilainen","year":"2009","journal-title":"J Neurosci"},{"issue":"7149","key":"ref21","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/nature05957","article-title":"Novel neurotrophic factor CDNF protects and rescues midbrain dopamine neurons in vivo","volume":"448","author":"P Lindholm","year":"2007","journal-title":"Nature"},{"issue":"1","key":"ref22","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.expneurol.2010.12.013","article-title":"Chronic infusion of CDNF prevents 6-OHDA-induced deficits in a rat model of Parkinson's disease","volume":"228","author":"MH Voutilainen","year":"2011","journal-title":"Experimental neurology"},{"issue":"2","key":"ref23","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.expneurol.2011.04.015","article-title":"Commentary on chronic infusion of CDNF prevents 6-OHDA-induced deficits in a rat model of Parkinson's disease. Merja H. Voutilainen et al.","volume":"230","author":"BJ Hoffer","year":"2011","journal-title":"Experimental neurology"},{"issue":"6","key":"ref24","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.3727\/096368911X600948","article-title":"CDNF Protects the Nigrostriatal Dopamine System and Promotes Recovery After MPTP Treatment in Mice","volume":"21","author":"M Airavaara","year":"2012","journal-title":"Cell Transplant"},{"issue":"4","key":"ref25","doi-asserted-by":"crossref","first-page":"286","DOI":"10.7150\/ijms.14152","article-title":"Enhancing Transgene Expression from Recombinant AAV8 Vectors in Different Tissues Using Woodchuck Hepatitis Virus Post-Transcriptional Regulatory Element","volume":"13","author":"L Wang","year":"2016","journal-title":"International journal of medical sciences"},{"issue":"2","key":"ref26","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0149776","article-title":"Comparative Analysis of the Effects of Neurotrophic Factors CDNF and GDNF in a Nonhuman Primate Model of Parkinson's Disease","volume":"11","author":"E Garea-Rodriguez","year":"2016","journal-title":"PloS one"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.expneurol.2013.06.002","article-title":"AAV2-mediated striatum delivery of human CDNF prevents the deterioration of midbrain dopamine neurons in a 6-hydroxydopamine induced parkinsonian rat model","volume":"248","author":"X Ren","year":"2013","journal-title":"Experimental neurology"},{"issue":"2","key":"ref28","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1038\/mt.2014.206","article-title":"Enhanced Efficacy of the CDNF\/MANF Family by Combined Intranigral Overexpression in the 6-OHDA Rat Model of Parkinson's Disease","volume":"23","author":"O Cordero-Llana","year":"2015","journal-title":"Molecular Therapy"},{"issue":"3","key":"ref29","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.ymthe.2005.10.008","article-title":"Efficient neuronal gene transfer with AAV8 leads to neurotoxic levels of tau or green fluorescent proteins","volume":"13","author":"RL Klein","year":"2006","journal-title":"Molecular therapy: the journal of the American Society of Gene Therapy"},{"issue":"2","key":"ref30","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1006\/exnr.2002.8006","article-title":"Aberrant sprouting and downregulation of tyrosine hydroxylase in lesioned nigrostriatal dopamine neurons induced by long-lasting overexpression of glial cell line derived neurotrophic factor in the striatum by lentiviral gene transfer","volume":"177","author":"B Georgievska","year":"2002","journal-title":"Experimental neurology"},{"issue":"2","key":"ref31","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1046\/j.1460-9568.2003.02456.x","article-title":"Long-term striatal overexpression of GDNF selectively downregulates tyrosine hydroxylase in the intact nigrostriatal dopamine system","volume":"17","author":"C Rosenblad","year":"2003","journal-title":"Eur J Neurosci"},{"issue":"6","key":"ref32","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1111\/j.1471-4159.2005.03139.x","article-title":"Long-term glial cell line-derived neurotrophic factor overexpression in the intact nigrostriatal system in rats leads to a decrease of dopamine and increase of tetrahydrobiopterin production","volume":"93","author":"A Sajadi","year":"2005","journal-title":"J Neurochem"},{"issue":"7","key":"ref33","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1111\/j.1742-4658.2012.08491.x","article-title":"Animal models of Parkinson's disease","volume":"279","author":"F Blandini","year":"2012","journal-title":"Febs J"},{"issue":"1","key":"ref34","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1007\/s13311-013-0234-1","article-title":"Animal Models of Parkinson's Disease: A Gateway to Therapeutics?","volume":"11","author":"WD Le","year":"2014","journal-title":"Neurotherapeutics"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.nbd.2013.04.011","article-title":"Enhanced neurotrophic distribution, cell signaling and neuroprotection following substantia nigral versus striatal delivery of AAV2-NRTN (CERE-120)","volume":"58","author":"CD Herzog","year":"2013","journal-title":"Neurobiology of disease"},{"issue":"Supplement 1","key":"ref36","doi-asserted-by":"crossref","first-page":"S143","DOI":"10.1016\/S1353-8020(11)70045-1","article-title":"Neurorestoration","volume":"18","author":"M Airavaara","year":"2012","journal-title":"Parkinsonism & Related Disorders"},{"issue":"1","key":"ref37","doi-asserted-by":"crossref","DOI":"10.1523\/ENEURO.0128-16.2017","article-title":"Intrastriatally Infused Exogenous CDNF Is Endocytosed and Retrogradely Transported to Substantia Nigra","volume":"4","author":"K M\u00e4tlik","year":"2017","journal-title":"eNeuro"},{"issue":"9","key":"ref38","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1038\/mt.2010.135","article-title":"A Phase I Study of Aromatic L-Amino Acid Decarboxylase Gene Therapy for Parkinson's Disease","volume":"18","author":"S Muramatsu","year":"2010","journal-title":"Molecular Therapy"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0179476","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T03:37:43Z","timestamp":1588995463000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0179476"}},"subtitle":[],"editor":[{"given":"R. Lee","family":"Mosley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2017,6,16]]},"references-count":38,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2017,6,16]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0179476","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,16]]}}}